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Summary Reye’s syndrome affects children with a
history of viral infection treated with
aspirin. Its pathogenesis is unclear. Tumour necrosis factor
(TNF) is released by macrophages activated by viral
infection, endotoxin, and phagocytosis, and it has been
shown to be a mediator of the toxic and metabolic effects of
endotoxaemia. The metabolic effects of endotoxin and TNF
are similar to those found in Reye’s syndrome. Raised levels
of TNF are released from macrophages treated with
non-steroidal anti-inflammatory drugs, and young animals
are known to be more sensitive than mature animals to both
TNF and endotoxin. These observations lead to the
hypothesis that an increased release of TNF in selected
young patients treated with aspirin contributes to the
development of Reye’s syndrome.
INTRODUCTION
Reye’s syndrome is an important cause of morbidity and
mortality in babies and children. It is characterised by
encephalopathy and acute fatty degeneration of the liver. 1,2
Antecedent viral infections (notably influenza A or B,
varicella, and occasionally gastrointestinal infections) are
recognised in over 90% of patients. Case-control studies
have shown that over 95% of children with the full-blown
syndrome have a history of aspirin ingestion.3 
We present evidence in support of the hypothesis
that increased release of tumour necrosis factor
(TNF) in salicylate-treated children contributes to the
pathogenesis of Reye’s syndrome.
ACTIVATION OF MACROPHAGES BY VIRUSES,
ENDOTOXIN, AND PHAGOCYTOSIS AND RELEASE OF TNF
Macrophages release a number of mediators when they
are activated by diverse stimuli.4,5 These mediators include
two forms of interleukin-1 (IL-1),6 arachidonate
metabolites,7,8 various enzymes,9,1O complement
components," interferon,12 and TNF.13 Viruses and
bacteria provoke the release of these mediators4,13 by means
of endotoxin 14 and lymphokines such as gamma interferon 15
and by stimulation of phagocytosis.16 The acute-phase
response,17,18 characterised by fever,18 myolysis,19 a fall in
serum zinc and iron,20,21 and de-novo synthesis of various
hepatocyte proteins,22 is mediated by IL-1.18,23 TNF
probably contributes to this host response. 13 Beutler et alz4
provide strong evidence that at least part of the lethal effect
of endotoxin is directly mediated by its stimulation of TNF
release by macrophages; a rabbit anti-TNF antiserum given
to lipopolysaccharide-challenged mice reduced lethality
several-fold. 25 Furthermore, TNF contributes to
inflammation by stimulation of granulocytes
(unpublished),26 endothelial cells, and fat cells.28
SIMILARITY BETWEEN TOXIC AND METABOLIC EFFECTS
OF TNF AND ENDOTOXIN AND THOSE FOUND IN REYE’S
SYNDROME
Laboratory rats given sub-lethal doses of Escherichia coli
endotoxin have shown metabolic changes (increased plasma
ammonia, free fatty acids, and serum lactate levels) and
histological changes (microvesicular fatty changes in liver
and ultrastructural evidence of hepatocyte mitochondrial
damage) similar to those found in Reye’s syndrome.29 Kim
et al30 showed that the function of hepatic Kupffer cells is
impaired and endotoxaemia commonly results after
infection with a number of viruses. Endotoxin has been
found in the plasma of patients with Reye’s syndrome,31 but
how it contributes to the pathogenesis of the syndrome is not
known. Concentrations of short-chain and medium-chain
fatty acid are raised in the serum of patients with Reye’s
syndrome.32 When these substances are injected into
experimental animals many of the clinical, pathological, and
biochemical features of the syndrome are reproduced.33
Studies of mice infected with influenza B showed them to
have a block in mitochondrial &bgr;-oxidation of fatty acids
with subsequent elevations in serum free-fatty-acid
concentrations.34 Released TNF can stimulate a catabolic
state characterised by hypertriglyceridaemia. Many of the
metabolic effects associated with Reye’s syndrome may be
mediated by monokines such as TNF or IL-1, and/or by
endotoxin released by bowel flora.
INCREASED RELEASE OF TNF BY MACROPHAGES
TREATED WITH NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS
We have shown an augmented release of TNF by
macrophages stimulated with lipopolysaccharide in the
presence of cyclo-oxygenase inhibitors. 12 The augmentation
of TNF release by non-steroidal anti-inflammatory drugs
parallels their potency-indomethacin is more potent than
aspirin, which is more potent than paracetamol (see table).
When a phagocytic stimulus (Staphylococcus aureus) was
incubated with freshly adherent peripheral blood human
monocytes for 14 h, a similar increase in TNF release after
non-steroidal anti-inflammatory drugs was seen: cells alone,
0 units TNF;35 phagocytic stimulus alone, 18 units;
phagocytic stimulus plus indomethacin 10 - mol/1, 360
units; 10 - mol/1, 250 units; 10 -7 mol/1, 50 units. Because
prostaglandins and the non-steroidal anti-inflammatory
inhibitors of their synthesis have been shown to modulate
IL-1 release7,36-38 it is likely that irregularities in this pathway
contribute to the enhanced release of other macrophage
products including TNF.
EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON
TNF RELEASE FROM MACROPHAGES*
*Mouse peritoneal macrophages were harvested 12 days after intraperitoneal
injection of 0 5 ml of a 1 :1 solution of complete Freund’s adjuvant and saline.
Cells were stimulated overnight with lipopolysalccharide in the presence of
inhibitors. 12
&dagger;Units of TNF are defined as the reciprocal dilution that produces half-
maximal cytotoxicity in a standard L929 mouse fibroblast assay.35
t Values significantly different from control (p > 0-05).
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AGE-RELATED TOXIC EFFECTS OF TNF IN ANIMALS
The median lethal dose for lipopolysaccharide is lower in
young than in mature animals. Young animals are also more
susceptible to gram-negative bacterial infections 14
(unpublished). Although many host factors contribute to
these findings, the greater susceptibility of young mice and
rats to the toxic effects of TNF (unpublished) may be
important. The fact that Reye’s syndrome is seldom found
in adults is consistent with increased susceptibility to TNF
in children.
HYPOTHESIS
We hypothesise that the metabolic irregularities seen
in Reye’s syndrome may be caused by salicylate-augmented
release of TNF (or a related cytotoxin such as IL-1 or
lymphotoxin) in children who are unusually sensitive to the
toxic effects of these factors. There is evidence of a link
between the hepatic metabolic changes observed in Reye’s
syndrome and TNF, and other idiopathic syndromes may
result from increased levels of TNF or related toxic
monokines. The acute fatty liver of pregnancy is one such
syndrome.39 The placenta is a rich reservoir of
macrophages40 that may become activated by a stimulus (as
yet unidentified) late in pregnancy. Despite their superficial
resemblance, Reye’s syndrome and the acute fatty liver of
pregnancy can be differentiated by hepatic mitochondrial
morphology and clinical course. Clearly, timing of events,
hormonal state and age of the patient, as well as other host
factors determine the outcome of an inflammatory pathway
that has gone awry. The augmented release of inflammatory
mediators such as IL-1 and TNF by macrophages treated
with inhibitors of prostaglandin biosynthesis, as well as the
sensitivity of young animals to these mediators, suggest a
novel pathogenetic mechanism for Reye’s syndrome.
Correspondence should be addressed to J. W. L., Cetus Immune Research
Laboratories, 3400 West Bayshore, Palo Alto, California 94303, USA.
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"Advanced cancer is a problem that requires teamwork. It
involves the needs of the patient, the resources of the family, the
therapeutic strageties of the doctor, the bedside and management
skills of the nurse, the emotional and spiritual support from social
worker and chaplain, and most important of all, the interplay and
fusion of these elements to produce a strategy agreeable to the
patient. The patient needs to feel actively concerned in his
management rather than a helpless prisoner.
This cannot be helped by the fact that nearly a third of dying
patients have little idea of their real situation. And basic teamwork is
greatly prejudiced when a third of doctors are unwilling to entrust to
capable and experienced nursing colleagues honest discussions with
the patients about the future. Although lies are rare, evasion is
common, but it is not enough to tell the patient the truth and let
them get on with it. This is a recent and growing tendency that can
be as damaging as uncertainty.
Prognosis should remain uncertain within limits, for that is the
truth of it. Patients should be encouraged to ask for information they
want, but not have it forced upon them. Someone dying may, early
in the illness, feel the need for less information than is required later
on. The young usually need more information than the old, but
generalisations are to be mistrusted. Relatives are to be listened to
courteously but the plea ’You won’t tell him will you, he couldn’t
stand it’ is often to be translated as ’You won’t tell him will you? I
don’t think I can handle it’."-ERIK WiLKES. Terminal care: how
can we do better? _7 R Coll Physicians Lond 1986; 20: 216-18.
